Medtronic Announces Breakthrough AI-Powered Electronic Alert System to Address Critical Delays in Valvular Heart Disease Treatment

Apr 15, 2026 08:02 CST Updated 08:02

Medtronic

Medical Device Manufacturer

On April 7, 2026, Medtronic released the latest data from the ALERT trial, a study that directly addresses critical pain points in the diagnosis and treatment of structural heart disease—uneven treatment and delays. An AI-powered electronic early warning system offers a practical solution.

PART.01

Pain Points in Valvular Heart Disease Diagnosis and Treatment: Treatment Delays Amid High Mortality Rates

Many people may be unfamiliar with the terms "structural heart disease," "aortic stenosis (AS)," and "mitral regurgitation (MR)," but in fact, they are not far from us. Simply put, the heart is like a precision "pump," and the valves are the "gates" on the pump that control the unidirectional flow of blood. Once these "gates" malfunction, blood cannot circulate properly, overburdening the heart and, in severe cases, even endangering life.

More distressing is the fact that many patients who meet the treatment criteria miss the optimal treatment window simply because they are not discovered in time or fail to have a treatment plan formulated. This is particularly true for severe aortic stenosis, where if symptoms occur and no treatment is received, the mortality rate within two years is extremely high. However, the issue of under-treatment for such patients remains prominent in clinical practice. The gaps in diagnosis and treatment are even more pronounced among ethnic minorities, patients with specific hemodynamic characteristics, and female patients.

PART.02

ALERT Trial: AI-Powered Sentinel Active Warning

To solve this problem, the ALERT trial specifically adopted Tempus Next, an AI-powered clinical pathway platform. It acts like a "smart sentinel," automatically identifying patients with severe AS or MR who meet guideline-directed treatment criteria but lack a clear treatment plan. It then sends electronic clinical notifications (ECNs) to clinicians via electronic health records, reminding doctors to intervene promptly.

This study is of extremely high value —— not only covering five healthcare systems and 35 hospitals in the United States, gathering 765 clinicians, and analyzing 2,016 echocardiogram datasets, but its findings were also presented at the 2026 American College of Cardiology Annual Scientific Session (ACC.26, March 28-30, New Orleans, USA) and simultaneously published in the *Journal of the American College of Cardiology* (JACC), showcasing its full authority.

PART.03

Test Results: Data Validation of AI Early Warning's Clinical Value

And the test results have brought hope to countless patients with valvular disease, as data speaks louder:

Compared with conventional diagnosis and treatment, the efficiency of electronic clinical notifications (ECNs) in alerting physicians to patients' cardiovascular conditions has increased by 27% (odds ratio 1.27; 95% confidence interval 1.05-1.54; p=0.007), successfully achieving the primary endpoint of the study—reducing the time for patients to receive surgical or transcatheter valve intervention, as well as the time to undergo multidisciplinary heart team (MHT) outpatient evaluation within 90 days.

Specifically, the key indicators for 90 days are even more highlighted:

Valve intervention rate increased by 40%: The proportion of patients receiving treatment rose from 9.6% to 13.4% (p=0.005);

Multidisciplinary Heart Team Assessment Rate Increased by 27%: Assessment Ratio Rose from 17.9% to 22.7% (p=0.005).

PART.04

Solving the Gap in Diagnosis and Treatment: Ensuring Timely Care for More Patients

Here, special mention must be made of Transcatheter Aortic Valve Implantation (TAVI) – this minimally invasive treatment method allows patients to have shorter hospital stays and faster recovery compared to traditional open-heart surgery. It has become a life-saving option for many patients with valvular disease, especially suitable for elderly and frail patients who cannot tolerate open-heart surgery. However, current data shows that 90% of TAVI procedures are concentrated among white patients, while the proportion of Black, Hispanic, and Asian minority patients receiving TAVI treatment is much lower than that of white patients. At the same time, women with aortic stenosis also face greater difficulty than men in obtaining timely evaluation and valve intervention, with a significant disparity in diagnosis and treatment.

"As clinicians, our primary task is to ensure that patients with severe heart valve disease receive timely treatment. The two-year mortality rate for untreated symptomatic severe aortic stenosis is very high, yet the issue of under-treatment remains serious, which hinders our efforts to promote life-saving valve intervention techniques across the entire healthcare system. The findings of this study highlight the value of real-time clinical alerts—they can accelerate diagnosis and specialist referrals, enabling more patients, regardless of race, ethnicity, region, or hemodynamic characteristics, to receive guideline-based, life-saving care."

——Chairman of the ALERT Trial Steering Committee, Wayne Batchelor from the U.S. Innova Medical System